MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF)

As of 25 July 2022, the Health Technology Assessment Council (HTAC) has finished the assessment and deliberation on *insulin glargine* and *insulin detemir* for type 1 and type 2 diabetes mellitus.

The HTAC hereby makes public its preliminary recommendation for the government financing of *insulin glargine and insulin detemir* through its inclusion in the PNF. Both drugs have shown comparable efficacy and acceptable safety profiles in both type 1 and type 2 diabetes mellitus patients as compared to Neutral Protamine Hagedorn (NPH) insulin. Furthermore, both interventions have shown lower risks of severe hypoglycemia.

The costing analysis of locally available insulin brands has shown that insulin glargine and detemir incur a higher individual cost and budget impact to the government as compared to NPH insulin. However, cost-effectiveness studies included in the WHO review have shown that the administration of these drugs are cost-effective as compared to NPH insulin.

Supporting studies that informed the recommendation of HTAC may be found in the accompanying Evidence Summary. All comments, inputs, and/or appeals may be submitted until **11 August 2022**, for the consideration of the HTAC, through email at <a href="https://htm.ncbi.nlm.nc

Please use the prescribed form for appeals which is accessible through this link: <a href="https://https.com/https://https.com/https://https://https.com/https://https

Should you wish to submit hard copies, you may drop them off at the following address: 4th floor, Philippine Blood Disease, and Transfusion Center, Lung Center Compound, Quezon Avenue, Quezon City.

ANNA MELISSA S. GUERRERO, MD, MPH (HTA)

Director IV Health Technology Assessment Division Health Regulation Team